Literature DB >> 15820309

Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations.

Anne Vankeerberghen1, Olga Scudiero, Kris De Boeck, Milan Macek, Pier Franco Pignatti, Noémi Van Hul, Hilde Nuytten, Francesco Salvatore, Giuseppe Castaldo, Daniela Zemkova, Vera Vavrova, Jean-Jacques Cassiman, Harry Cuppens.   

Abstract

Human beta defensins contribute to the first line of defense against infection of the lung. Polymorphisms in these genes are therefore potential modifiers of the severity of lung disease in cystic fibrosis. Polymorphisms were sought in the human beta-defensin genes DEFB1, DEFB4, DEFB103A, and DEFB104 in healthy individuals and cystic fibrosis (CF) patients living in various European countries. DEFB1, DEFB4, and DEFB104 were very polymorphic, but DEFB103A was not. Within Europe, differences between control populations were found for some of the frequent polymorphisms in DEFB1, with significant differences between South-Italian and Czech populations. Moreover, frequent polymorphisms located in DEFB4 and DEFB104 were not in Hardy Weinberg equilibrium in all populations studied, while those in DEFB1 were in Hardy Weinberg equilibrium. Sequencing of a monochromosomal chromosome 8 mouse-human hybrid cell line revealed signals for multiple alleles for some loci in DEFB4 and DEFB104, but not for DEFB1. This indicated that more than one DEFB4 and DEFB104 gene was present on this chromosome 8, in agreement with recent findings that DEFB4 and DEFB104 are part of a repeat region. Individual DEFB4 and DEFB104 PCR amplification products of various samples were cloned and sequenced. The results showed that one DNA sample could contain more than two haplotypes, indicating that the various repeats on one chromosome were not identical. Given the higher complexity found in the genomic organization of the DEFB4 and DEFB104 genes, association studies with CF lung disease severity were performed only for frequent polymorphisms located in DEFB1. No association with the age of first infection by Pseudomonas aeruginosa or with the FEV1 percentage at the age of 11-13 years could be found.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820309     DOI: 10.1016/j.ygeno.2005.02.003

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  7 in total

Review 1.  The changing of the guard: Molecular diversity and rapid evolution of beta-defensins.

Authors:  Colin A Semple; Phillipe Gautier; Karen Taylor; Julia R Dorin
Journal:  Mol Divers       Date:  2006-11       Impact factor: 2.943

2.  A case of bilateral endophthalmitis and carriage of beta-defensin 1 44CC genotype.

Authors:  James Carter; Amanda J Churchill; Chris Gorman; Richard Haynes
Journal:  Br J Ophthalmol       Date:  2007-09       Impact factor: 4.638

Review 3.  Defensins as anti-inflammatory compounds and mucosal adjuvants.

Authors:  Karl G Kohlgraf; Lindsey C Pingel; Deborah E Dietrich; Kim A Brogden
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

4.  pH modulates the activity and synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37.

Authors:  Mahmoud H Abou Alaiwa; Leah R Reznikov; Nicholas D Gansemer; Kelsey A Sheets; Alexander R Horswill; David A Stoltz; Joseph Zabner; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 5.  Efficiency of Antimicrobial Peptides Against Multidrug-Resistant Staphylococcal Pathogens.

Authors:  Mi Nguyen-Tra Le; Miki Kawada-Matsuo; Hitoshi Komatsuzawa
Journal:  Front Microbiol       Date:  2022-06-09       Impact factor: 6.064

6.  Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis.

Authors:  Edward J Hollox; Jane Davies; Uta Griesenbach; Juliana Burgess; Eric W F W Alton; John A L Armour
Journal:  J Negat Results Biomed       Date:  2005-12-07

7.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.